首页> 美国卫生研究院文献>World Journal of Gastroenterology >Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro
【2h】

Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro

机译:生长抑素受体2亚型对胰腺癌细胞的抗血管生成作用:体外抑制血管内皮生长因子和基质金属蛋白酶-2的表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To investigate the anti-angiogenic effect of somatostatin receptor subtype 2 (SSTR2) gene transfer into pancreatic cancer cell line PC-3, and the mechanisms involved in this effect.METHODS: The full length human SSTR2 cDNA was introduced into pancreatic cancer cell line PC-3 by lipofectamine-mediated transfection. Positive clones were screened by G418 and stable expression of SSTR2 was detected by immunohistochemistry SABC methods and RT-PCR. Enzyme-linked immunosorbent assay (ELISA) was used to detect vascular endothelial growth factor (VEGF) levels in the cell culture supernatants of SSTR2-expressing cells, vector control and mock control cells. Furthermore, the expressions of VEGF and matrix metalloproteinase-2 (MMP-2) were detected by immunohistochemistry SABC methods and RT-PCR in these cells.RESULTS: VEGF levels in the cell culture supernatants were significantly reduced in the SSTR2-expressing cells (first week, 172.63 ± 21.2 ng/L and after two months, 198.85 ± 26.44 ng/L) compared with the vector control (first week, 790.39 ± 86.52 ng/L and after two months, 795.69 ± 72.35 ng/L) and mock control (first week, 786.42 ± 90.62 ng/L and after two months, 805.32 ± 84.36 ng/L) (P < 0.05). The immunohistochemical assay showed a significant reduction of the integral optical density of VEGF and MMP-2 in the SSTR2-expressing cells (42.25 ± 8.6 and 70.5 ± 6.25, respectively) compared with the vector control (85.75 ± 12.9 and 110.52 ± 13.5, respectively) and mock control (82.6 ± 9.28 and 113.56 ± 9.62, respectively) (P < 0.05). Conversely, the average gray value of VEGF and MMP-2 was significantly increased in the SSTR2-expressing cells (121.56 ± 8.43 and 134.46 ± 19.95, respectively) compared with the vector control (55.72 ± 5.6 and 62.26 ± 12.68, respectively) and mock control cells (58.48 ± 6.2 and 65.49 ± 9.16, respectively) (P < 0.05). Moreover, the expressions of VEGF mRNA and MMP-2 mRNA were significantly reduced in the SSTR2-expressing cells (0.1384 ± 0.017 and 0.2343 ± 0.070, respectively) compared with the vector control (1.024 ± 0.117 and 0.806 ± 0.119, respectively) and mock control (1.085 ± 0.105 and 0.714 ± 0.079, respectively) (P < 0.05).CONCLUSION: The expression of reintroduced human SSTR2 gene exerts its antiangiogenic effects by down-regulating the expressions of the factors involved in tumor angiogenesis and metastasis, suggesting SSTR2 gene transfer as a new strategy of gene therapy for pancreatic cancer.
机译:目的:探讨生长抑素受体亚型2(SSTR2)基因转移到胰腺癌细胞株PC-3中的抗血管生成作用及其机制。方法:将人SSTR2全长cDNA导入胰腺癌细胞PC-3系通过lipofectamine介导的转染。用G418筛选阳性克隆,采用免疫组织化学SABC法和RT-PCR检测SSTR2的稳定表达。酶联免疫吸附试验(ELISA)用于检测表达SSTR2的细胞,载体对照和模拟对照细胞的细胞培养上清液中的血管内皮生长因子(VEGF)水平。通过免疫组织化学SABC法和RT-PCR检测这些细胞中VEGF和基质金属蛋白酶-2(MMP-2)的表达。结果:在表达SSTR2的细胞中,细胞培养上清液中的VEGF水平显着降低。与对照相比(第一周为790.39±86.52 ng / L,两个月后为795.69±72.35 ng / L)和模拟对照相比,每周172.63±21.2 ng / L和两个月后为198.85±26.44 ng / L) (第一周为786.42±90.62 ng / L,两个月后为805.32±84.36 ng / L)(P <0.05)。免疫组织化学分析显示,与载体对照(分别为85.75±12.9和110.52±13.5)相比,表达SSTR2的细胞中VEGF和MMP-2的整体光密度显着降低(分别为42.25±8.6和70.5±6.25)。 )和模拟控制(分别为82.6±9.28和113.56±9.62)(P <0.05)。相反,与载体对照(分别为55.72±5.6和62.26±12.68)和模拟载体相比,表达SSTR2的细胞中VEGF和MMP-2的平均灰度值显着增加(分别为121.56±8.43和134.46±19.95)。对照细胞(分别为58.48±6.2和65.49±9.16)(P <0.05)。而且,与载体对照(分别为1.024±0.117和0.806±0.119)和模拟载体相比,在表达SSTR2的细胞中VEGF mRNA和MMP-2 mRNA的表达显着降低(分别为0.1384±0.017和0.2343±0.070)。结论:重新导入的人SSTR2基因的表达通过下调与肿瘤血管生成和转移有关的因子的表达而发挥抗血管生成作用,提示SSTR2基因的表达(P <0.05)。(P <0.05)。转移作为胰腺癌基因治疗的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号